Literature DB >> 11502813

Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations.

L Persani1, S Borgato, A Lania, M Filopanti, G Mantovani, M Conti, A Spada.   

Abstract

Both cAMP production by adenylyl cyclase and cAMP degradation by phosphodiesterases account for intracellular cAMP levels. We previously demonstrated an increased phosphodiesterase activity in GH-secreting adenomas bearing the gsp oncogene. Here we characterize both the activity and the expression of cAMP-specific phosphodiesterase genes in the human pituitary and in gsp+ and gsp- GH-secreting adenomas and analyze the impact of this intracellular feedback mechanism on the levels of cAMP-responsive element-binding protein phosphorylation. Normal pituitary and gsp- GH-secreting adenomas showed similar phosphodiesterase activities, and 7-fold higher levels were observed in gsp+ tumors. In these tumors the increased activity was mainly owing to isobutyl-methyl-xanthine-sensitive phosphodiesterase 4 and to isobutyl-methyl-xanthine-insensitive isoforms. By semiquantitative RT-PCR, all phosphodiesterase 4 transcripts were expressed in the normal and tumoral pituitary. However, the levels of phosphodiesterase 4C and 4D messenger RNAs were significantly higher in gsp+ than in gsp- GH-secreting adenomas and normal pituitary. Expression of the thyroid-specific isobutyl-methyl-xanthine-insensitive phosphodiesterase 8B was absent in the normal pituitary but detectable in almost all GH-secreting adenomas and higher in gsp+ (P < 0.02). Therefore, this study provides a characterization of phosphodiesterase expression in human pituitary and demonstrates a dramatic induction of the cAMP-specific phosphodiesterases 4C and phosphodiesterases 4D and phosphodiesterases 8B in gsp+ GH-secreting adenomas. Similar levels of cAMP-responsive element-binding protein phosphorylation were observed in gsp- and gsp+ GH-secreting adenomas; however, phosphodiesterase blockade caused an increase in cAMP-responsive element-binding protein phosphorylation that was significantly higher in gsp+ than in gsp- adenomas. Because cAMP-responsive element-binding protein represents the principal end point of the cAMP pathway, these results suggest that the enhanced phosphodiesterase activity may have a significant impact on the phenotypic expression of gsp mutations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502813     DOI: 10.1210/jcem.86.8.7779

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways.

Authors:  Paraskevi Xekouki; Monalisa Azevedo; Constantine A Stratakis
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

Review 2.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

3.  Interaction of AIP with protein kinase A (cAMP-dependent protein kinase).

Authors:  Marie Helene Schernthaner-Reiter; Giampaolo Trivellin; Constantine A Stratakis
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

4.  Dependence of multidrug resistance protein-mediated cyclic nucleotide efflux on the background sodium conductance.

Authors:  Marek Kucka; Karla Kretschmannova; Takayo Murano; Chung-Pu Wu; Hana Zemkova; Suresh V Ambudkar; Stanko S Stojilkovic
Journal:  Mol Pharmacol       Date:  2009-11-10       Impact factor: 4.436

Review 5.  Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors.

Authors:  Anelia Horvath; Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

6.  Analysis of GNAS1 and PRKAR1A gene mutations in human cardiac myxomas not associated with multiple endocrine disorders.

Authors:  G Mantovani; S Bondioni; S Corbetta; L Menicanti; B Rubino; E Peverelli; P Labarile; C Dall'Asta; B Ambrosi; P Beck-Peccoz; A G Lania; A Spada
Journal:  J Endocrinol Invest       Date:  2009-04-29       Impact factor: 4.256

7.  cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.

Authors:  Graeme B Bolger; Mariana F Bizzi; Sergio V Pinheiro; Giampaolo Trivellin; Lisa Smoot; Mary-Ann Accavitti; Márta Korbonits; Antonio Ribeiro-Oliveira
Journal:  Endocr Relat Cancer       Date:  2016-05       Impact factor: 5.678

8.  Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia.

Authors:  Lingzhi Zhang; Fiona Murray; Anja Zahno; Joan R Kanter; Daisy Chou; Ryan Suda; Michael Fenlon; Laura Rassenti; Howard Cottam; Thomas J Kipps; Paul A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-25       Impact factor: 11.205

9.  Frequency and effect on serum TSH of phosphodiesterase 8B (PDE8B) gene polymorphisms in patients with sporadic nonautoimmune subclinical hypothyroidism.

Authors:  P Agretti; G De Marco; C Di Cosmo; B Bagattini; E Ferrarini; L Montanelli; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2014-01-09       Impact factor: 4.256

10.  Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function.

Authors:  Lisette Arnaud-Lopez; Gianluca Usala; Graziano Ceresini; Braxton D Mitchell; Maria Grazia Pilia; Maria Grazia Piras; Natascia Sestu; Andrea Maschio; Fabio Busonero; Giuseppe Albai; Mariano Dei; Sandra Lai; Antonella Mulas; Laura Crisponi; Toshiko Tanaka; Stefania Bandinelli; Jack M Guralnik; Angela Loi; Lenuta Balaci; Gabriella Sole; Alessia Prinzis; Stefano Mariotti; Alan R Shuldiner; Antonio Cao; David Schlessinger; Manuela Uda; Gonçalo R Abecasis; Ramaiah Nagaraja; Serena Sanna; Silvia Naitza
Journal:  Am J Hum Genet       Date:  2008-06       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.